Quarterly ResultMay 11, 2026, 04:13 PM
Septerna Q1 Net Loss Narrows to $8.6M; Cash $522.1M; Pipeline Advances
AI Summary
Septerna, Inc. reported a significantly reduced net loss of $8.6 million for Q1 2026, down from $21.5 million in Q1 2025, with revenue increasing to $26.5 million. The company maintained a strong cash position of $522.1 million, expected to fund operations into 2029. Septerna also highlighted positive Phase 1 data for SEP-631, supporting its advancement to Phase 2b in H2 2026, and initiated a Phase 1 trial for SEP-479. Chief Medical Officer Jae Kim, M.D., will be departing.
Key Highlights
- Net loss significantly narrowed to $8.6 million in Q1 2026 from $21.5 million in Q1 2025.
- Revenue increased to $26.5 million in Q1 2026 from $0.2 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $522.1 million as of March 31, 2026.
- Cash runway expected to fund operations at least into 2029.
- Positive Phase 1 clinical results for SEP-631 support Phase 2b development in H2 2026.
- Phase 1 clinical trial initiated for SEP-479 for hypoparathyroidism, with data expected late 2026/early 2027.
- Chief Medical Officer, Jae Kim, M.D., informed the company of his decision to depart.